Hydroxychloroquine Alternatives in 2025: Exploring Tofacitinib and More
In 2025, several alternatives to Hydroxychloroquine have emerged, offering options for treating conditions like rheumatoid arthritis. Tofacitinib (Xeljanz) stands out as a Janus kinase inhibitor, providing rapid relief of symptoms. Each alternative comes with its own set of advantages and disadvantages, making it crucial for patients and healthcare providers to weigh the benefits and potential risks. Understanding these alternatives can lead to informed treatment decisions.
Read more